Most prominent challenges in translational neuroscience and strategic solutions to bridge the gaps: Perspectives from an editorial board interrogation

作者：Dirk M. Hermann, Marco Bacigaluppi, Claudio L. Bassetti, Gabrio Bassotti, Johannes Boltze, Andrew Chan, Turgay Dalkara, Ádám Dénes, Exuperio Díez‐Tejedor, Richard Dodel, Thorsten R. Doeppner, Egor Dzyubenko, Ayman ElAli, Tamàs Fülöp, Alexander Gerhard, Bernd Giebel, Janine Gronewold, Matthias Gunzer, Thomas Heinbockel, Kaibin Huang, Marcello Iriti, Hans‐Otto Karnath, Kasteleijn-Nolst Trenite, Ertuğrul Kılıç, Giuseppe Lanza, Arthur Liesz, Tim Magnus, Jessica Mandrioli, Ayan Mohamud Yusuf, Thomas Müller, Suyue Pan, Luca Peruzzotti‐Jametti, Stefano Pluchino, Ryszard Pluta, Aurel Popa‐Wagner, Ameneh Rezayof, Mohamed L. Seghier, Xinhua Shu, Vikramjeet Singh, Jussi Sipilä, Mark Slevin, Yamei Tang, Georgios Tsivgoulis, Giustino Varrassi, Chen Wang, Bayram Yılmaz, Maha S. Zaki, Jinwei Zhang · 发表于：Exploration of neuroscience · 年份：2025 · DOI：10.37349/en.2025.1006106 · 被引用次数：9 · 研究领域：Bioinformatics and Genomic Networks、Computational Drug Discovery Methods

Recent progress in translational neuroscience has significantly advanced our understanding of neurological diseases. Research progress closely went in line with innovations in research methods, which have expanded our insights considerably beyond previous limits. However, despite the development of disease-modifying treatments, therapeutic options in brain diseases still lag behind fundamental discoveries in basic neuroscience. This perspective examines the factors that hinder clinical progress in translational neuroscience and provides solutions on how to overcome them. Editorial board members of Exploration of Neuroscience were interrogated about the most prominent challenges they see in translational neuroscience and about possible ways to overcome these issues. Key challenges were seen at the interface between experimental research and clinical studies by several members, both from the basic and applied neuroscience fields, which include the selection of appropriate study readouts and endpoints. The establishment of refined study endpoints, combined with biomarkers capable of predicting treatment responses in human patients, will be crucial for the successful clinical implementation of new therapies. Further obstacles were found in the standardization of experimental models, interventions, and assessments both in animals and humans, as well as in the development of personalized treatment strategies. These challenges can be addressed through more clearly defined experiment...